NASDAQ:VNDA Vanda Pharmaceuticals Q3 2026 Earnings Date & Estimates $4.01 -0.04 (-0.99%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$3.99 -0.02 (-0.52%) As of 10/23/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Vanda Pharmaceuticals is estimated to report Q3 2026 earnings on Wednesday, October 28, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateOctober 28, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Vanda Pharmaceuticals in Q3 2026Vanda Pharmaceuticals is expected to post earnings of -$0.72 per share on revenue of $69.20 million. In the same quarter a year earlier Vanda Pharmaceuticals reported -$0.38 per share on revenue of $56.26 million. Vanda Pharmaceuticals last reported on August 5, 2026, posting -$1.04 per share and missing the -$0.5825 consensus estimate. Vanda Pharmaceuticals has beaten the consensus EPS estimate in 2 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.72Expected Revenue$69.20 millionPrior-Year EPS-$0.38Prior-Year Revenue$56.26 millionExpected Revenue Growth+23.0%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.04 (Missed by -$0.4575)Last Quarter Revenue$50.53 millionEPS Beat Rate2 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Vanda Pharmaceuticals Q3 2026 Earnings FAQ When does Vanda Pharmaceuticals report Q3 2026 earnings? Vanda Pharmaceuticals (NASDAQ:VNDA) is estimated to report Q3 2026 earnings on Wednesday, October 28, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Vanda Pharmaceuticals' Q3 2026 earnings call? Vanda Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, October 28, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Vanda Pharmaceuticals? Analysts expect Vanda Pharmaceuticals to post earnings of -$0.72 per share for Q3 2026. How much revenue is Vanda Pharmaceuticals expected to report? The consensus revenue estimate for Vanda Pharmaceuticals is $69.20 million for Q3 2026. Vanda Pharmaceuticals Earnings HeadlinesVanda Pharmaceuticals (VNDA) Set to Post Earnings on WednesdayOctober 23 at 2:10 AM | americanbankingnews.comVanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026October 21, 2026 | prnewswire.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 25 at 1:00 AM | Banyan Hill Publishing (Ad)Vanda Pharmaceuticals: Cash Is Running Out Faster Than The LaunchesOctober 15, 2026 | seekingalpha.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramOctober 15, 2026 | finanznachrichten.deVanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary EndpointOctober 15, 2026 | benzinga.comSee More Vanda Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vanda Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vanda Pharmaceuticals and other key companies, straight to your email. Email Address About Vanda PharmaceuticalsVanda Pharmaceuticals (NASDAQ:VNDA) is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, D.C., the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets. Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome. The company also markets Fanapt (iloperidone), an atypical antipsychotic used to treat schizophrenia in adults and approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. In addition to its commercial products, Vanda has pursued clinical development programs addressing disorders such as gastroparesis and other conditions involving sleep, circadian rhythms and the central nervous system. The company’s strategy centers on advancing therapies through clinical development and regulatory review while expanding the use of its approved medicines.View Vanda Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating CostsWhy Western Digital's AI Storage Boom Defies the Chip Sell-Off Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
